ChemPartner(SZ:300149)2025-09-19 09:38Group 1: Financial Performance and Market Strategy - The company aims to achieve significant revenue growth from the Boston laboratory, which is a key step in its global strategy, targeting increased overseas business and enhancing existing operations [2] - The company's revenue returned to a growth trajectory in the first half of the year, with profits turning positive, despite fluctuations in the stock price due to macroeconomic factors [3] - Domestic CRO service orders increased by over 40% year-on-year in the first half of the year, indicating strong market demand [5] Group 2: Operational Updates and Challenges - The company has temporarily halted operations at the Qidong large molecule production base due to a lack of improvement in the domestic CDMO market, while the Zhangjiang facility can meet current production demands [4] - The company is actively expanding its full-package service business, with multiple projects in negotiation, typically valued in the tens of millions of RMB [5] - The company is considering the acquisition of the Qidong facility based on market conditions and existing rental agreements [4] Group 3: Investor Relations and Future Plans - The company is in the process of responding to inquiries from the Shenzhen Stock Exchange regarding its refinancing efforts, which are progressing in an orderly manner [6] - The company emphasizes that its stock price is influenced by various factors, including market sentiment and economic conditions, and advises investors to be aware of investment risks [6] - The establishment of an industrial fund aims to drive business growth by investing in innovative pharmaceutical companies, ensuring business synergy with the company's operations [5]